Leucine Supplementation and Skeletal Muscle Disuse

Leucine and Skeletal Muscle Disuse: Clinical Anti-Atrophic Effectiveness and Related Mechanisms

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01192009

Enrollment

Registered

2010-08-31

Start date

2011-04-30

Completion date

2013-02-28

Last updated

2013-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disuse Atrophy

Keywords

Leucine, Skeletal Muscle Disuse, Atrophy, Proteolysis

Brief summary

Leucine supplementation is widely known for promoting strong influence on skeletal muscle remodeling. This study aims to evaluate the effect of leucine supplementation on disuse-induced skeletal muscle atrophy.

Interventions

DIETARY_SUPPLEMENTLeucine

7.2 g of leucine during 2 weeks

DIETARY_SUPPLEMENTPlacebo

7.2 g of alanine during 2 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

MALE

Age

18 Years to 35 Years

Healthy volunteers

Yes

Inclusion criteria

* Clinical diagnosis of anterior cruciate ligament injury * Physically active * Must be able to swallow tablets * Non-smokers * Do not use nutritional supplements

Exclusion criteria

* Post-surgical complications

Design outcomes

Primary

Measure	Time frame
Skeletal muscle structure (cross-sectional area)	2 weeks

Secondary

Measure	Time frame
Molecular signalling pathways (hypertrophy, atrophy, and inflammation)	2 weeks

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026